Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: The present invention is related to HMGB1 antagonists and, in particular, HMGB1 tetramer peptidomimetics which have been stabilized with at least one azatide linkage, such as K883. The present invention is also related to pharmaceutical compositions comprising HMGB1 antagonists such as K883.

Abstract: The present invention is related to the use of HMGB1 antagonists, specifically derivatives of K883 in the treatment and/or prevention and/or inhibition of neuropathy pain, and in particular diabetic neuropathy in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: Methods and systems are described for detecting the likelihood of patent ductus arteriosus (PDA) in an infant using electrocardiogram and photoplethysmographic pulse signals obtained from the upper body and foot of the infant.

Abstract: Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics.

Abstract: Systems and methods of mitigating one or more bodily effects of a shock condition experienced by an animal (including a human, e.g., a patient) are described. One exemplary method includes providing a device for applying non-invasive neurostimulation to the animal's trigeminal nerve. The method also includes applying the non-invasive neurostimulation to the animal's trigeminal nerve, thereby increasing oxygen flow to the animal's brain and/or reducing brain inflammation.

Abstract: Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.

Abstract: Methods of diagnosis and methods of treatment and prevention for autism spectrum disorder are provided using decoy antigens to maternal brain-reactive antibodies.

Abstract: A method and an apparatus for treating a patient suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade, by electrically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Abstract: The present disclosure relates to compositions, methods of preparation of the compositions, and methods including administration of said compositions for the prevention of neurological damage associated with cerebral ischemia.

Abstract: A hospital gown including an upper body portion and a lower body portion. The upper body portion includes a neck opening, a front opening extending vertically along the upper body portion and in communication with the neck opening, and a series of complementary closures disposed vertically along the front opening so that the front opening is configured to transition between an open condition and a closed condition. The lower body portion includes a pair of legs extending downwardly from the upper body portion, an opening extending vertically along the inseam of each leg of the pair of legs, and a series of complementary closures disposed vertically along each opening such that each opening is configured to transition between an open condition and a closed condition.

Abstract: Provided are CD4+ T-cell-based compositions and methods for treating hypertension.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising providing the subject with an acoustic energy stimulus derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: A method of treating a sterile inflammatory condition in a subject using an isolated dermcidin peptide or an active fragment thereof of or an active analog thereof is provided. Also provided is a method of inhibiting organ transplantation-associated is chemia/reperfusion and/or organ transplantation-associated inflammation.

Abstract: Disclosed are apparatuses and methods for reducing or limiting blood loss and reducing bleed time in a subject by combined vagus and trigeminal stimulation. The apparatuses and methods may activate (e.g., electrically) one or more branches of the trigeminal nerve and may concurrently (at overlapping or near-overlapping time) independently activate the vagus nerve. This activation may be invasive or non-invasive.

Abstract: Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Abstract: Embodiments of systems and methods of the present disclosure include a database layer queries patient-related raw data from data tables of distinct data collection services, normalizes the patient-related raw data to produce common format normalized patient-related data, and stores the common format normalized patient-related data. An algorithmic processing layer, in real-time, analyzes the common format normalized patient-related data based on patient-related data metrics, a healthcare facility-related data metrics, or both, to determine patient-related data points, where each patient-related data point is associated with a respective threshold condition and a respective ranking score, ranks the patient-related data points based on the threshold condition and the ranking score to determine a priority, and generates actionable medical directives related to patients, where the actionable medical directives cause real-time operational changes in the way that the healthcare facility services the patients.

Abstract: Methods are disclosed for treating a subject with metabolic syndrome, fatty liver disease, insulin resistance, inflammation or elevated body weight using hepatic ultrasound.

Abstract: Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Abstract: Methods and pharmaceutical compositions comprising one or more mTOR inhibitors such as sirolimus and one or more receptor tyrosine kinase inhibitors such as nintedanib are disclosed for treating vascular lesions and hereditary hemorrhagic telangiectasia.